Search Results

Coya Therapeutics, Inc. announces the expansion of its research collaboration with the Houston Methodist Research Institute (“HMRI”) through a sponsored research agreement (SRA) covering multiple initiatives.

Health Data Analytics Institute announced a joint presentation next week with Houston Methodist on how they are “Deploying Clinical AI at Scale,” a key advance in unleashing a long-awaited data-driven transformation in medical care.

SOLASCURE Ltd, a biotechnology company developing a novel treatment to transform chronic wound care, announced it has been selected for Innovate UK’s Global Incubator Programme in Houston, US.

The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce the return of the Biotherapies Pavilion at the 2024 AABB Annual Meeting, which will take place Oct. 19-22 in Houston, Texas.

Renal Research Institute, a global leader in dialysis and nephrology research and a subsidiary of Fresenius Medical Care AG, announced together with the Karolinska Institutet a joint symposium, “Prevention of CKD progression: the impact of new therapeutics.” The Karolinska Institutet is one of the world’s leading medical universities.

Coya Therapeutics, Inc. announces the presentation of data demonstrating the role of the peripheral immune system in the pathophysiology of Frontotemporal Dementia (FTD) from a biomarker study conducted at the Houston Methodist Hospital by Dr. Stanley Appel and Dr. Alireza Faridar and funded by the Houston Methodist Clinical Scholar Award Program.

Researchers at the Pacific Northwest Research Institute (PNRI) and collaborating institutions have made a groundbreaking discovery that could significantly advance our understanding of genomic disorders.